Abstract
Physical activity (PA) is an effective way of increasing cognitive and emotional health and counteracting many psychiatric conditions. Numerous neurobiological models for depression have emerged in the past 30 years but many struggle to incorporate the effects of exercise. The hippocampus and pre-frontal cortex (PFC) containing predominantly glutamate neurotransmission, are the centres of changes seen in depression. There is therefore increasing interest in glutamatergic systems which offers new paradigms of understanding mechanisms connecting physical activity, stress, inflammation and depression, not explained by the serotonin theories of depression. Similar hippocampal glutamate dysfunction is observed in many other neuropsychiatric conditions. Excitatory glutamate neurones have high functionality, but also high ATP requirements and are therefore vulnerable to glucocorticoid or pro-inflammatory stress that causes mitochondrial dysfunction, with synaptic loss, culminating in depressed mood and cognition. Exercise improves mitochondrial function, angiogenesis and synaptogenesis. Within the glutamate hypothesis of depression, the mechanisms of stress and inflammation have been extensively researched, but PA as a mitigator is less understood. This review examines the glutamatergic mechanisms underlying depression and the evidence of physical activity interventions within this framework. A dynamic glutamate-based homeostatic model is suggested whereby stress, neuroinflammation and PA form counterbalancing influences on hippocampal cell functionality, which manifests as depression and other neuropsychiatric conditions when homeostasis is disrupted.
Introduction
Depression is defined by diagnostic criteria from the Diagnostic and Statistical Manual 5 (DSM5). including depressed mood or anhedonia (loss of interest or pleasure), with additional symptoms including appetite or weight changes, difficulty sleeping, diminished ability to think or concentrate, fatigue or loss of energy, feelings of worthlessness, or excessive guilt and suicidality (). The heterogeneity of clinical presentations, presence of comorbid conditions and psychosocial confounding variables is challenging for the reproducibility of studies of the underlying mechanisms.
Major depressive disorder (MDD) is a leading cause of global disease burden that affects over 300 million persons worldwide (). This burden is high across the entire lifespan, genders, global distributions and the incidence is rising. The total estimated number of people living with depression worldwide increased by 18.4% between 2005 and 2015 to 322 million equating to 4.4% of the world’s population, with a lifetime risk of 15%–18%. In terms of disability, depression ranked third in the causes of years lived with disabilities (). Importantly, no reduction in the global prevalence or burden has been detected for depression or anxiety since 1990, despite compelling evidence of interventions that reduce their impact (). The high costs to individuals and society demand efficacious treatments, yet 30% of patients fail to respond to current serotoninergic-based pharmacotherapeutics, while 70% do not achieve complete remission (). Outcomes for Major Depressive Disorder (MDD) are associated with a reduced life expectancy of 10–20 years, despite active treatment. This is mostly due to cardiometabolic disease related to chronic treatments and physical inactivity (). The high levels of treatment resistance, undesirable side effects, and the high economic and social cost to society have prompted a diversification of the search for effective treatment options ().
Physical activity (PA) in its many forms has, since antiquity, been associated with antidepressant effects although the neurobiological mechanisms have remained elusive due to the heterogeneity of clinical depression and difficulty of studying neurochemistry in vivo, large differences in individual responses and poor uptake of sustained exercise interventions ().
Volumetric magnetic resonance (MR) imaging of depressed patients has established for some time that, more than other brain areas, the hippocampus shows volume reduction in chronic psychiatric conditions which is partially restored by regular exercise (, ). However, previous models of depression, such as the monoamine theory of serotonin and noradrenaline, fail to provide a mechanistic framework for these effects, leading to a historical lack of research into exercise as a treatment.
There have been many neurobiological theories of depression, with many overlapping themes. The theories of monoamines, hypothalamic pituitary adrenal (HPA) axis hyperactivity, reduced neuroplasticity, hypoGABA-ergic theory and neuroinflammation are all validated hypotheses (–). Glutamate neurotransmission and associated mitochondrial function within the hippocampus, underpin and therefore unify many of these related concepts. However advances since the 2000s in knowledge of glutamate neurotransmission in the limbic and prefrontal cortex, have generated an overarching glutamate hypothesis of depression, which has a wide evidence base and increasing clinical acceptance (). Importantly, a glutamate-based model of depression provides mechanistic explanations for how physical activity impacts on mental health. Therefore, the aim of this review is to provide an integrative view of neuroplasticity, glutamatergic and inflammatory theories of depression, centred on mitochondrial dysfunction in the hippocampus and to describe the integral role of PA within this schema. As depression is by far the most researched field for the effects of PA, we discuss the mechanisms for a model in relation to depression and then extend to other disorders. Given the rising societal prevalences of mental health disorders, social isolation, stress and sedentariness, the need to research the precise effects of exercise is more important than ever. Psychiatric conditions where PA has an evidence base and areas where PA remains under-researched are also discussed.
Glutamatergic model of depression
The glutamate hypothesis of depression emerged in the 1990s, when antagonists of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor, produced antidepressant-like effects in mice (). In a seminal human trial by Berman in 2000, ketamine (a long-standing anaesthetic agent and glutamate NMDA receptor antagonist) demonstrated a rapid-onset and prolonged mood improvement in MDD, including in cases of treatment-resistant depression (TRD) (). Further proof of concept emerged when Magnetic Resonance Spectroscopy (MRS) scans revealed decreased levels of glutamatergic metabolites in the medial frontal cortex in patients with depression () and MR imaging showed volume reductions in MDD patients in the hippocampus which is a glutamate neurotransmission predominant area ().
This prompted research into glutamate receptor subtypes and ligands as possible therapeutic targets and agents respectively. There are two classes of receptors that exhibit functional differences (). Inotropic GluRs (iGluRs) are ligand-gated ion channels for fast signal transmission. Metabotropic receptors, GluRs (mGluRs) are G protein-coupled receptors (GPCRs) which control cellular processes via G protein signalling cascades. The first iGluR and mGluR members were cloned in 1989, and 1991 respectively and intense research into receptor subtypes and ligands has continued ever since in the search for possible new paradigms of treatment (, ).
Specific iGluR agonists have revealed three main subfamilies of receptors, named after the agonist: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPARs), kainic acid (KARs), and N-methyl-D-aspartate (NMDARs) (). NMDARs, the target site of ketamine, were first cloned in 1991 (). Within each receptor group genetic mechanisms generates further structural variations within the receptor subunits, which creates functional diversity (). This receptor-encoded complexity sets glutamate apart from other neurotransmitters and enables the functional capacity required for complex processing in pattern and memory encoding.
Experimentally depression and anxiety like behaviours are reproduced by stimulating or blocking the subunits of these receptors with pharmacological ligands. Where specific receptor ligands are unknown, gene targeting models in mice can investigate the contribution of subunit subtypes. In a knockout mouse model of the GluN2A subunit of NMDARs, mice exhibited reduced anxiety and depression behaviour during experimental conditions such as the forced swim test and tail suspension tests (). Similarly effects were seen with deletions of GluN1 GluN2B NMDA subunits, or the administration of the GluN2B antagonist Ro 25-6981 ().
The precise mechanisms of NMDAR antagonism reducing depression are still unclear as pure NMDAR antagonists alone do not reduce depressive symptoms (). The antidepressant effects of NMDAR antagonism in preclinical experiments require simultaneous activation of AMPARs (30). Although the reasons are unclear, the GluA1 subunit of AMPAR seems to be related to dysfunctional synaptic plasticity during depression. The selective deletion of this GluA1 AMPA subunit in the hippocampus, reduces experience dependent behavioural despair (31).
Glutamate is the predominant excitatory neurotransmitter in the central nervous system (CNS) accounting for over 90% of excitatory function (32). Glutamatergic synapses are found throughout the CNS but are especially concentrated in the hippocampus, amygdala, caudate nucleus, pre frontal cortex (PFC) and the cerebellum (33).
Glutamate neurone distribution therefore neatly overlays the main anatomical areas implicated in depression, namely the hippocampus and PFC. The excitatory nature of glutamate neurotransmission and vast array of receptor combinations, enables the complex synaptic activity required by the hippocampus for rapid pattern recognition. Additional functions include: spatial reference and working memory, pattern discernment and mapping, emotional activation and decision making, all in response to new environmental stimuli. Impairment of these functions leads to low mood and anhedonia. Prefrontal inhibition leads to inflexible negative biases in cognition, predisposing to rigidly held negative beliefs and poor motivation, leading to negative cognition arising the low mood (34).
It is the unique properties of glutamatergic neurotransmission, enabling memory and cognition, that create a vulnerability to dysfunction, leading to depression and other conditions. Unlike other neurotransmitters, glutamate causes synaptic excitation at micromolar concentrations and cannot then be enzymically deactivated in the synaptic space. Therefore, to avoid the lethal effects of synaptic overstimulation and excitotoxcity, adjacent astrocytes have developed a receptor-based system of reuptake transporters: GLT-1, GLAST, and EAAT (35). After uptake, glutamate is metabolised within the astrocyte, to non-excitatory glutamine and returned to the neurone via the glutamate–glutamine cycle, or oxidised and entered into the citric acid cycle as a fuel substrate. This active system of glutamate uptake against steep concentration gradients, requires significant amounts of ATP energy and therefore mitochondrial involvement. Glutamate neurotransmission therefore accounts for 80% of entire brain energy expenditure, and 20% of the total body expenditure. Hence, prolonged mental concentration, involving widespread glutamatergic activity, causes sensations of fatigue (36, 37).
The link of the glutamine-glutamate cycle with the tricarboxylic acid (TCA) cycle in astrocyte mitochondria, enables glutamate neurotransmission to recycle some of the cellular energy loss, thus avoiding potential local energy mismatch issues. Despite this, the net demands on astrocytic mitochondria remain very high and still render the hippocampus very vulnerable to metabolic overload or inflammatory stress. This dependency of hippocampal function and therefore mood, on mitochondrial function, is demonstrated by resveratrol, a drug whose action is purely to increase mitochondrial function. In animal models of depression, significant increases in mood are observed, without a direct effect on neurotransmitters (38).
Mitochondria, as providers of ATP energy for the cell, therefore also have a role in sensing and regulating cellular ATP requirements and oxidative stress. Mitochondria are therefore sensitive to numerous signalling pathways involving oxidative stress and inflammation. As such, the glutamate-based model of depression, through glutamatergic astrocytic mitochondria, demonstrates direct links between depression symptoms and physiological systems such as HPA stress responses, physical activity and less intuitively, the immune system.
Decades of depression mechanistic research have converged on three main, but interrelated, systems associated with depression; stress via the HPA axis, inflammation and neuroplasticity. This review discusses these aspects in relation to glutamate function, the hippocampus and physical activity.
Glutamate mediates the relationship of stress with depression
The hippocampus, within the limbic system, is the primary centre of receiving and interpreting external stimuli and determining appropriate and rapid emotional, cognitive, neurological and endocrine responses. The primary endocrine response, when threats are perceived, is via the HPA axis, culminating in glucocorticoid release from the adrenal glands. The process starts when impulses from the hippocampus excite corticotrophin release factor (CRF) cells in the paraventricular nucleus (PVN) of the hypothalamus. The excitation is via glutamate receptors, demonstrating one of many relationships between glutamatergic activity and the endocrine stress response (39). Common to many glutaminergic microcircuits, GABA interneurones control the effect of excitation by inhibiting CRF cell secretion. GABA inhibition is itself deactivated when GABA ion channels open, causing depolarisation. Depolarisation is regulated by chloride cotransporters, which determine the transmembrane electrochemical gradient (40). In animal models, psychological stress and the inflammatory mediator IL-6 affect the number and function of these cotransporters and therefore act to deactivate GABA inhibition, hence increasing CRF and cortisol secretion (41). Cortisol acts via glucocorticoid (GR) receptors to cause GABA inhibition of CRF secretion and hippocampal deactivation to complete the negative feedback loop. Such close hippocampal-hypothalamic interactions explain the tight association of stress and mood.
In the short term, stress-induced deactivation of GABA, enabling cortisol-mediated protective mechanisms, is an appropriate physiological response to a perceived threat. Cortisol, the primary adrenal glucocorticoid, has anti-inflammatory and catabolic effects, necessary to contain infection, trauma and other defined periodic immune stresses.
Medium term stress, over weeks or months, such as bereavement, divorce, financial or criminal issues, and illness, produce perpetuation of the HPA axis activation. This occurs as a result of a self-amplification effect, whereby HPA glucocorticoids provide feedback to the CNS and activate GR receptors on the original glutamate presynaptic neurones, provoking further CRF cell activation. Although the underlying precipitants and perpetuating causes are not fully established, external agents that promote glutamatergic excitation and suppress GABA inhibition are clearly involved. This is sometimes referred to as “the GABA-ergic deficit hypothesis of major depressive disorder” (42). The high levels of circulating cortisol causes persistent GR receptor activation and a positive feedback loop.
GR receptor-stimulation also causes astrocytic release of ATP causing microglial proliferation, the release of pro-inflammatory mediators and the release of the growth factor Brain Derived Neurotrophic Factor (BDNF) (43). In animal models, the effects of persistent glucocorticoids on glutamate neurones are: increased glutaminergic excitability with astrocytic decline, reduced astroglial plasticity and reduced dendritic connectivity in hippocampal and frontal cortex regions (44, 45). Collectively this manifests as anxiety, depressed mood, disturbed or excessive sleep, fatigue, memory and cognitive problems, behavioural responses and, in extreme circumstances, suicide (46). Outside of the CN, cortisol causes depressed humoral and cellular immunity with dysmetabolic and vascular changes.
In short term stress, this cluster of cortisol-mediated, energy-conserving and self-protective symptoms, is seen in the “sickness behaviour” of people with severe infections. It also features behavioural changes, such as anorexia, fatigue, loss of interest in usual daily activities, social withdrawal, listlessness or malaise, hyperalgesia, sleep disturbances, and cognitive dysfunction (47). The “pathogen defence hypothesis of depression” is supported by the ancestral and continued proximity of alleles for depression and pro-inflammatory factors (48). This inflammatory depression of hippocampal function as an ancient protective mechanism becomes problematic in modern life when HPA activation is persistent.
The glutamate model explains why reduced physical activity, low motivation and depressed mood may in fact be inherent protective adaptations to stress and may explain the poor motivation and uptake of exercise in interventions for major depression.
From experimental simulations of stress, creating subtypes such as intermittent, restrained, or unpredictable forms, it is clear that high persistent cortisol levels also feature a pro-inflammatory state. This less understood aspect of the stress response is due to cortisol-mediated short term rises in plasma IL-6, TNF-alpha, and monocyte nuclear-factor kappa-B (NFkB), partially facilitated by the sympathetic nervous system (SNS) (49–51). As stress persists there is increasing SNS mediated B-adrenoceptor-activated monocyte migration into the CNS, causing pro-inflammatory cytokine secretion (52). Clearly, stress, anti-inflammatory HPA-stress responses, and raised pro-inflammatory mediators, have a complicated and sometimes seemingly contradictory relationship, although this may simply reflect different phases in the stress response and emphasises the dynamic nature of the hippocampal/HPA systems. This co-existent state of pro-inflammatory cytokines and raised CNS cortisol, causes double stimulation of astrocyte and neuronal receptors, leading to cellular exhaustion and apoptosis. This, in turn, leads to more chronic and structurally consolidated stress phenotypes (53).
Prolonged stress
Continual suppression of GABA inhibition leads to glutamate overstimulation and eventual exhaustion of CRF cells and the HPA axis, resulting in low levels of glucocorticoids despite ongoing stress. Low circulating glucocorticoids are seen in atypical depression, post-traumatic stress disorder (PTSD) and in suicide attempts (54). Reduced circulating glucocorticoids remove the suppressive influence the HPA axis exerts on pro-inflammatory mediators. The resulting pro-inflammatory state causes dendritic damage, reduced synaptic plasticity and the transformation of astrocytes into pro-inflammatory phenotypes, which then secrete cytokines in a “feed-forward” manner. Pro-inflammatory cytokines then act to reduce mitochondrial biogenesis leading to metabolic insufficiency with autophagy and apoptosis.
In severe or prolonged stress, cumulative cell loss eventually results in loss of volume of hippocampal and prefrontal areas on MRI, with reductions in glutamate neurotransmission on MRS brain imaging, as described above. These macroscopic changes represent significant neuronal loss and degeneration and are commensurate with the increasing evidence of chronic MDD or other major psychiatric conditions, converting to neurodegenerative conditions such as Dementia and Parkinson’s Disease (55, 56). The transition from MDD to diseases featuring progressive neurological decline is unpredictable and poorly understood, but is consistent within the framework of the glutamatergic model.
Severe stress experienced in early life seems to amplify pro-inflammatory responses to stress in adulthood, possibly as a result of defective HPA/hippocampal integration during development, although the mechanism is not fully understood (57). The resulting chronic pro-inflammatory states may explain the connection between adverse life events in childhood and subsequent depression and chronic physical disease. Childhood Adverse Life Experiences (ALEs) are associated with a 2.4-times increase in mortality at the age of 65, compared to controls (58).
Glutamate, inflammation and depression
Patients with major depression have significantly higher plasma concentrations of the cytokines TNF-α and IL-6 than controls (59). Whilst CNS inflammatory mediators form part of the depression-associated stress response above, primary inflammatory conditions themselves can invoke depression (60). The relationship between inflammation and depression therefore is rather circular. Regardless of whether the origin is centrally derived or peripheral, inflammatory mediators produce similar effects on glutamate microcircuits to those seen with stress, namely increased oxidative and nitrosative stress, with reduced BDNF and other growth factors needed for maintenance of the glutamate astro-neuronal unit. Oxidative stress results from the imbalance of between mitochondrial reactive oxygen species ROS production and removal and therefore excess superoxide and other ROS within the cell. This arises from overproduction and or deceased antioxidant capacity. Oxidative damage affects many cellular components, including lipids DNA and proteins and mitochondria themselves. Up to 2% of consumed oxygen is converted to superoxide through electron leakage within the mitochondrial ETC (61). In energetic cells, such as neurons, with raised mitochondrial activity, ROS production is increased (62). However ROS production is also increased when mitochondria become impaired and electron leakage increases (63).
In addition to the direct effects on cells, ROS also stimulates pro-inflammatory cytokines such as IL-6 and TNFa. This provokes a ligand-activated transcription factor: peroxisome-proliferator-activated receptor-γ (PPAR-γ). PPAR-γ suppresses pro-inflammatory transcription factors and activates mitochondrial biogenesis. This key metabolic controller also promotes anti-oxidant and angiogenesis pathways and raises glucose and lactate availability in astrocytes (64).
The high oxidative activity of neuronal mitochondria, makes the mitochondria ETC itself vulnerable to functional overload, producing excess ROS, ETC damage, then increased electron leakage and ROS in a vicious circle. Mitochondrial function declines and antioxidant defences are reduced. The increased oxidative state damages organelles and if prolonged risks progression to autophagy, via mTor signalling and apoptosis via activated Caspases (65, 66).
Effects of physical activity in increasing neuronal mitochondrial biogenesis
Counterbalancing these risks of functional overload are trophic mechanisms to promote cell enhancement and growth, which are strongly related to physical activity. PGC1a is a transcriptional co-activator stimulated by physical activity which, via PPAR-γ, facilitates mitochondrial biogenesis (67). This effect is not just confined to muscle. In the hippocampus, exercise induced biogenesis increases levels of oxidative phosphorylation giving neuroprotection to glutamate neurones, vulnerable to mitochondrial insufficiency (68). PGC1a is activated in muscle by a mitochondrial energy-sensing kinase, AMPK and stress inducible kinases including p38 mitogen-activated protein kinase (MAPK). Muscle activity in the form of exercise, particularly endurance exercise, creates energy demand and optimally stimulate production, with effects in the CNS (69).
In patients with treatment resistant depression (TRD), that is not responsive to serotoninergic drugs, it would be expected that exercise would stimulate increased PGC1a and hence hippocampal mitogenesis to reduce pro-inflammatory cytokines and improve mood. This was in fact observed in a study of 12 weeks of an aerobic exercise protocol in TRD patients (70). Increased mood correlated with reduction of IL-1β levels. Notably the higher the circulating basal TNF-α levels the greater the effects of PA on reducing the depression.
Physical activity also serves to lose weight, particularly visceral adiposity, which coupled with sedentariness are potent contributors of circulatory IL-6 and TNF-α, sometimes described as the “diseaseome of physical inactivity” (71).
Randomised trials show positive results for exercise improving mental health but due to the heterogeneity in responses, effect sizes are smaller than in large observational studies (72).
Most evidence indicates that exercise, especially aerobic exercise improves depression and anxiety outcome measures, with similar effect sizes to psychopharmacological treatments. Resistance exercise trials also show reduction in symptoms (73). Exercise benefits are seen in different forms of depression such as in the elderly and children and young people (74, 75). Notably the mental health effects continue during the intervention but decline rapidly after discontinuation (76). Sustained beneficial effects seem to be maintained only above a threshold of 150 mins per week, as reflected by WHO exercise guidelines (77). The considerable variation of exercise effects across patient populations and forms of activity indicates the need to understand the underlying mechanisms, although this has proved elusive. The discovery of the kynurenine pathway, linking muscle activity with neurophysiology was a major development in understanding.
Physical activity and the kynurenine pathway
A key inflammatory pathway in CNS glutamatergic systems, relevant to PA, is the kynurenine pathway. The kynurenines are bioactive metabolites of tryptophan (TRP), deriving from the gut and are therefore an important feature of traffic in the gut-muscle-brain axis (78). Much interest has focused on members of this pathway in terms of mediating inflammatory CNS conditions. In the brain kynurenine metabolites are generated locally by microglia or enter via the blood-brain barrier (BBB) from the circulation. Importantly, excess kynurenine substrate (KYN) is prevented from entering the brain, through conversion by exercising muscle into kynurenic acid (KA), which cannot pass the BBB. In the brain, kynurenine catabolism divides into two pathways depending on local conditions: Either pro-inflammatory neurotoxic metabolites including Quinolinic acid, (QA) (a glutamate NMDA receptor agonist), or neuroprotective metabolites including kynurenic acid, KynA (an NMDAr antagonist). Initially, the kynurenine pathway was thought to cause depression by depleting serotonin, but the principal site of action is now known to be glutamatergic transmission (79). The ratio of KynA to QuinA has been demonstrated to be low (i.e., neurotoxic), due to the excess QuinA released from microglial cells, in the anterior cingulate cortex in depression (80). Moreover, the kynurenine pathway itself is modulated peripherally in adverse conditions such as infection and stress. However, in exercise, beneficial effects occur, with muscle enzyme increases or decreases, causing changes in the KynA:QuinA ratio (81). In addition to reducing CNS entry of kynurenine, exercise promotes enzymic switches towards an increased KynA/QuinA ratio, which promotes PGC1a mediated mitochondrial biogenesis. This is responsible for the beneficial effects of exercise such as improved energy homeostasis, the promotion of an anti-inflammatory environment, and neuroprotection, and is thought to be one of the mechanisms underlying the beneficial effects of exercise on depression (82).
Neuroplasia and depression
From a structural point of view, the hippocampus is a central processor of incoming information, rapidly sorting, evaluating and storing sensory input and connecting with the PFC, amygdala and HPA axis for cognitive, emotional and endocrine responses. The speed and complexity of this most challenging of brain activities requires high levels of neurogenesis and neuroplasticity in these exclusively glutamate neurones. Neurogenesis, the formation of new neurone cells, continues throughout adult life, only in two areas of the adult brain; a zone of the lateral ventricles and the dentate gyrus of the hippocampus (83). Neurogenesis seems a prerequisite for memory formation. Neuroplasticity involving the growth, consolidation and pruning of hippocampal dendrites is a vital part of memory consolidation and memory removal, when modelled by activity-dependent changes in synaptic transmission such as long-term potentiation (LTP) and long-term depression (LTD) (84). Stress acts through many mechanisms to impair synaptic plasticity and neurogenesis, by direct decrease of dendritic branching or activating corticosteroids to downregulate neurogenesis (85). Severe and continued impairment is reflected in overall loss of hippocampal volume.
As described above, the link between impairment in the memory forming regions of the hippocampus and depression is strong but not self-evident. However evidence is incontrovertible that reduced neuroplasticity in areas of memory function correlates to symptoms of depression (86). Trophic factors that promote synaptogenesis or improve mitochondrial function to fuel the process therefore also improve mood. Growth factors, or neurotrophins, are produced locally or enter via the BBB from muscle and other tissues. The mammalian neurotrophins include: Brain derived neurotrophic factor (BDNF), insulin like growth factor (IGF-1) vascular endothelial growth factor (VEGF) fibroblast growth factor (FGF-2) epidermal growth factor (EGF) nerve growth factor (NGF) (87). Irisin, produced in muscle, is involved in the regulation of neural differentiation, neuroplasticity and energy expenditure (88).
BDNF is a vital growth factor for sustaining neurones and promoting growth and repair and is synthesised in neurones in physiological circumstances and astrocytes during inflammation or injury (89). BDNF expression is highest in hippocampal and frontal areas corresponding to emotional and cognitive function. It is well established that serum BDNF levels are reduced in depression and are normalised with treatment by antidepressants or PA (90). PA increases plasma levels threefold, partially due to muscle derived BDNF and contributes to brain plasticity and neurogenesis. Aerobic and anaerobic exercises promote neurogenesis via BDNF, lactate and Vascular Endothelial Growth Factors (VEGF). In contrast, for resistance exercise, neuroplasticity and neurogenesis is mediated via muscle derived irisin and IGF-1 (91).
As BDNF expression features highly in those hippocampal circuits responsible for interpreting external sensory information, then environmental enrichment appears to increase BDNF further and be the primary source of the ability of environmental enrichments to enhance cognitive processes (92).
Summary of neurological effects of PA
Physical activity significantly improves brain function as measured by neuronal survival, resilience to brain physical insults, cognitive function, brain vascularisation, neuroplasticity and neurogenesis, neuroinflammatory stability and resistance to the effects of ageing. Physical activity mechanisms operate not in isolation but form part of the network of the gut-muscle-brain axes, in addition to environmental stressors as depicted in Figure 1.
Figure 1
The primary focus of these effects centres on the hippocampus and involves glutamatergic neurotransmission. Key to maintaining homeostasis and promoting growth are the neurotrophic factors produced locally or peripherally in muscle, which emphasises the crosstalk between brain and the musculoskeletal system. In terms of neuropsychiatric conditions, these changes have the effect of stabilising mood, reducing negative cognitive bias, increasing resilience to psychosocial stress and increasing motivation (93). There is also evidence of exercise directly stimulating hippocampal circuitry from other parts of the CNS. Glutamate neurotransmission frequencies are seen to increase almost instantaneously to the start of exercise. The mechanisms and neural pathways are unclear but the neuroplastic promoting effects on hippocampal neuronal health are similar to the other effects of PA (94).
In addition to the direct neurohumoral benefits of exercise, PA also provides numerous indirect benefits due to the nature of different sports and the external environment. Complex tasks, such as strategizing and decision making, risk management and social interaction, all stress and stimulate hippocampal and PFC circuits in beneficial ways (95). Exercise tends to behaviourally influence other positive activities such as diet quality and social interactions, all with individual beneficial effects on neuroimmunology (96).
In a negative context, the importance of environment is illustrated by the increasing incidence of mental health disorders in professional athletes, illustrating the power of environmental stress factors to override the antidepressant effects of even large quantities of physical activity (97).
PA in other neuropsychiatric conditions
The physiological effects of exercise impact positively on the vast majority of psychiatric conditions from affective disorders, schizophrenia disorders to trauma-based and developmental disorders.
Unlike the glutamate model, many of the previous depression models of pathogenesis do not transfer across diagnostic boundaries. In a previous review we described the validity of the glutamatergic model across diverse neuropsychiatric categories, involving common themes such as excitotoxicity, and suggest possible novel treatment avenues (98). Through cytokines and neurotrophins the glutamate model is also able to provide a theoretical basis for physical activity impacting on depression and other psychiatric disorders. Many disorders that feature depression and hippocampal pathology, respond to PA as described. However, other disorders may improve along different channels and await further research. A full description of the clinical research on the benefits of physical activity on the spectrum of neuropsychiatric conditions is outside the scope of this mechanism-based review. However, Table 1 summarises the evidence of effect, taken from systematic reviews, where available, in the main DSM-5 disease categories.
Table 1
| DSM V classification | Evidence of PA preventing disease | Evidence of PA treating symptoms | Volume of evidence |
|---|---|---|---|
| Depressive disorders | +++ | +++ | ++++ |
| Anxiety | +++ | +++ | ++++ |
| Schizophrenia | 0 | ++ | (99, 100) |
| Bipolar disorder | 0 | ++ | Paucity (101) |
| Neurodevelopmental disorders | |||
| Autism | 0 | + | + (102) |
| ADHD | 0 | + | + (103) |
| Intellectual disorders | 0 | + | + (104) |
| Trauma and stressor related disorders | |||
| PTSD | 0 | ++ | + (105) |
| OCD | 0 | + | + (106, 107) |
| Personality disorders | 0 | 0 | No studies |
| Neurodegenerative disorders | |||
| Alzheimers | +++ (108) | ++ (109) | ++ |
| Parkinsons | +++ (110) | +++ (111) | +++ |
Quantity of evidence for physical activity influencing neuropsychiatric conditions (Symbols “+”, “++”, “+++” and “++++” refer to approximate proportional quantities, relative to zero).
It is interesting to note the contemporaneous nature of much of this research, which demonstrates how psychopharmacology has dominated psychiatric treatment research in previous decades. Also, the inconsistency in the volume of research for each disorder, across the spectrum, is evident in Table 1. While there is a substantial research base into PA for depression and neurodegenerative disorders, research into bipolar disorder and schizophrenia is a more recent phenomenon and much smaller in volume. Research into clinical benefits in the remaining categories is at an embryonic stage, despite strong evidence of underlying glutamatergic dysfunction and therefore plausible responses to PA. At the time of writing there are no identifiable studies of PA in Personality Disorders. The reasons for this are not clear.
The seesaw model of hippocampal glutamatergic function
Multiple previous models of depression (inflammatory, neuroplastic) have been discussed in relation to increasing evidence supporting glutamate neurotransmission as the key player. Many previous theories consider systems in isolation and without temporal features. As a result most theories, although partially correct, struggle to incorporate or explain the complex effects of exercise on depression neurobiology.
The conclusion from this review is that physical activity, HPA stress, and neuroinflammation are three distinct, necessary and constant influences forming a dynamical balance or “seesaw”, as depicted in Figure 2, that controls glutamate neurotransmission in the hippocampus and PFC, to maintain mood and cognitive function. Numerous other factors such as diet and genetic influences are relevant but for simplification only the best known influencers of glutamatergic stability are included.
Figure 2
It is the hope that providing a robust simple model will enable researchers to identity gaps and conduct much needed research in this field.
The implication of this model is that physical activity is not an adjunctive treatment for depression, but an essential component of basic functioning, without which harm is caused. This absence of PA, (sedentariness), is predicted this model to tip the balance towards a pro-inflammatory state. Indeed chronic sedentariness is seen to correlate with chronic low-grade pro-inflammatory states leading to depression and cardiometabolic disease.
Too much of a good thing
A second implication is that moderate amounts of hippocampal stimulation from the HPA axis and neuroinflammation systems are required for system stability, despite often being considered as pathological forces. With dynamic systems the quantity and temporal behaviour sometimes determine the beneficial or harmful nature of the agent. Taking this to an extreme, to demonstrate proof of model concept, it can be seen that even beneficial physical activity, in excessive amounts, can cause a pro- inflammatory state and be harmful. Excessive exercise training schedules with insufficient recovery time and extreme ultra-distance running events causing muscle injury and pro-inflammatory states are common examples of this (112–114).
Too little of a bad thing
The converse scenario of the seesaw model shows too little stimulation from HPA or inflammatory systems. This leads to reduced levels of BDNF, reduced synaptoplasticity and a slow decline in glutamate functionality. Clinically there is evidence of anxiety and depression resulting from lack of stress and stimulation (115). Social isolation is related to this. Small amounts of “healthy” acute stress such as public speaking, produce cortisol mediated dentate gyrus neurogenesis leading to improvements in memory and performance 2 weeks after stress exposure (116).
How much physical activity is required to maintain health or homeostatic balance, is seen in this model to be a varying and dynamic quantity, depending on the counterbalancing stress and inflammation within the individual. Hence, increased stress, tipping glutamate neurones towards dysfunction can be rebalanced by increased amounts of physical activity and this is borne out in clinical research. The underlying state of individual balances may explain some of the variation in responses of individuals to mass exercise interventions for mental health and the difficulties in prescribing optimal exercise interventions for individuals.
Another application of this model is in the depression associated with the chronic metabolic diseases, such as diabetes, characterised by low grade pro-inflammatory states. In this case, systemic cytokines enter the brain causing neuroinflammation with reduced mood and cognition. This condition has only relatively recently been recognised despite affecting up to 20% of patients (117).
As a result there is very little research available to date, on PA interventions to improve this form of depression in chronic disease groups. Limited studies have shown improvement in mood and motivation in chronic lung disease, diabetes and rheumatoid patients after exercise, independent of the state of the underlying condition (118).
The important implication of the glutamate model is that treatment of chronic disease-associated depression, by physical activity, not only reduces depression symptoms in current disease, but is neuroprotective against future chronic metabolic disease-associated-neurodegeneration, such as diabetes associated dementia and Parkinson’s disease. This is also a recently recognised and significant clinical burden, which is not currently addressed by conventional disease management (119, 120).
In a parallel process, the glutamate balance model also indicates that chronic psychiatric conditions, such as Major Depressive Disorder, could theoretically progress on to later neurodegenerative disease. Conditions where PA is less studied, such as Borderline Personality Disorder, theoretically risk future neurodegenerative disease, because they already demonstrate the pre-requisites of chronic inflammation and reduced hippocampal volume as a result of developmental in HPA responses (121). This emphasises the urgent need for neuroprotective exercise research in these poorly studied groups and other psychiatric conditions that stem from Adverse Childhood Experiences (ACEs).
Lastly it is important to distinguish this dynamic glutamate “seesaw” model based on the non-linear laws of cellular energetics and energy balance, from the psychological associations observed in depression. Hence stress and depression are often associated with reduced physical activity levels, despite the fact that this model clearly indicates the need to increase. The psychology of why human behaviour does not necessarily follow what the underlying balance state is indicating, is complex and outside the subject of this review.
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
TolentinoJCSchmidtSL. DSM-5 criteria and depression severity: implications for clinical practice. Front Psychiatry. (2018) 9:450. 10.3389/fpsyt.2018.00450
2.
GBD 2017 Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. (2018) 392(10159):1789–858. 10.1016/S0140-6736(18)32279-7
3.
VosTFlaxmanADNaghaviMLozanoRMichaudCEzzatiMet alYears lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. (2012) 380:2163–96. 10.1016/S0140-6736(12)61729-2
4.
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of mental disorders in 204 countries and territories, 1990–2019: a systematic analysis from the global burden of disease study 2019. Lancet Psychiatry. (2022) 9(2):137–50. 10.1016/S2215-0366(21)00395-3
5.
ShalimovaABabasievaVChubarevVNTarasovVVSchiöthHBMwinyiJ. Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics. (2021) 22(8):485–503. 10.2217/pgs-2020-0157
6.
ChesneyEGoodwinGMFazelS. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. (2014) 13(2):153–60. 10.1002/wps.20128
7.
StachowiczKSowa-KućmaM. The treatment of depression - searching for new ideas. Front Pharmacol. (2022) 13:988648. 10.3389/fphar.2022.988648
8.
SmithPJMerwinRM. The role of exercise in management of mental health disorders: an integrative review. Annu Rev Med. (2021) 72:45–62. 10.1146/annurev-med-060619-022943.
9.
CzéhBLucassenPJ. What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated?Eur Arch Psychiatry Clin Neurosci. (2007) 257(5):250–60. 10.1007/s00406-007-0728-0
10.
EricksonKIVossMWPrakashRSBasakCSzaboAChaddockLet alExercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. (2011) 108(7):3017–22. 10.1073/pnas.1015950108
11.
HirschfeldRM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. (2000) 61(Suppl 6):4–6.
12.
HolsboerF. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. (2000) 23(5):477–501. 10.1016/S0893-133X(00)00159-7
13.
MassartRMongeauRLanfumeyL. Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression. Philos Trans R Soc Lond B Biol Sci. (2012) 367(1601):2485–94. 10.1098/rstb.2012.0212
14.
LuscherBShenQSahirN. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. (2011) 16(4):383–406. 10.1038/mp.2010.120
15.
GałeckiPTalarowskaM. Inflammatory theory of depression. Psychiatr Pol. (2018) 52(3):437–47. 10.12740/PP/76863
16.
SanacoraGTreccaniGPopoliM. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. (2012) 62(1):63–77. 10.1016/j.neuropharm.2011.07.036
17.
TrullasRSkolnickP. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. (1990) 185(1):1–10. 10.1016/0014-2999(90)90204-j
18.
BermanRMCappielloAAnandAOrenDAHeningerGRCharneyDSet alAntidepressant effects of ketamine in depressed patients. Biol Psychiatry. (2000) 47(4):351–4. 10.1016/s0006-3223(99)00230-9
19.
MoriguchiSTakamiyaANodaYHoritaNWadaMTsugawaSet alGlutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Mol Psychiatry. (2019) 24(7):952–64. 10.1038/s41380-018-0252-9
20.
BremnerJDNarayanMAndersonERStaibLHMillerHLCharneyDS. Hippocampal volume reduction in major depression. Am J Psychiatry. (2000) 157(1):115–8. 10.1176/ajp.157.1.115
21.
WillardSSKoochekpourS. Glutamate, glutamate receptors, and downstream signalling pathways. Int J Biol Sci. (2013) 9(9):948–59. 10.7150/ijbs.6426
22.
HollmannMO'Shea-GreenfieldARogersSWHeinemannS. Cloning by functional expression of a member of the glutamate receptor family. Nature. (1989) 342(6250):643–8. 10.1038/342643a0
23.
MasuMTanabeYTsuchidaKShigemotoRNakanishiS. Sequence and expression of a metabotropic glutamate receptor. Nature. (1991) 349:760–5. 10.1038/349760a0
24.
NakanishiS. Molecular diversity of glutamate receptors and implications for brain function. Science. (1992) 258:597–603. 10.1126/science.1329206
25.
MoriyoshiKMasuMIshiiTShigemotoRMizunoNNakanishiS. Molecular cloning and characterization of the rat NMDA receptor. Nature. (1991) 354:31–7. 10.1038/354031a0
26.
SommerBMonyerHWisdenWVerdoornTABurnashevNSprengelRet alGlutamate-gated ion channels in the brain. Genetic mechanism for generating molecular and functional diversity. Arzneimittelforschung. (1992) 42(2A):209–10.
27.
Boyce-RustayJMHolmesA. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology. (2006) 31:2405–14. 10.1038/sj.npp.1301039
28.
KiselycznykCJuryNJHalladayLRNakazawaKMishinaMSprengelRet alNMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism. Behav Brain Res. (2015) 287:89–95. 10.1016/j.bbr.2015.03.023
29.
BorbélyÉSimonMFuchsEWiborgOCzéhBHelyesZ. Novel drug developmental strategies for treatment-resistant depression. Br J Pharmacol. (2022) 179(6):1146–86. 10.1111/bph.15753
30.
FreudenbergFCelikelTReifA. The role of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity?Neurosci Biobehav Rev. (2015) 52:193–206. 10.1016/j.neubiorev.2015.03.005
31.
FreudenbergFMarxVMackVLayerLEKlugmannMSeeburgPHet alGlua1 and its PDZ-interaction: a role in experience-dependent behavioral plasticity in the forced swim test. Neurobiol Dis. (2013) 52:160–7. 10.1016/j.nbd.2012.12.003
32.
MeldrumBS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr. (2000) 130(4S Suppl):1007S–15S. 10.1093/jn/130.4.1007S
33.
NiciuMJKelmendiBSanacoraG. Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav. (2012) 100(4):656–64. 10.1016/j.pbb.2011.08.008
34.
PriceRBDumanR. Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model. Mol Psychiatry. (2020) 25(3):530–43. 10.1038/s41380-019-0615-x
35.
BakLKSchousboeAWaagepetersenHS. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. (2006) 98(3):641–53. 10.1111/j.1471-4159.2006.03913.x
36.
AttwellDLaughlinSB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab. (2001) 21(10):1133–45. 10.1097/00004647-200110000-00001
37.
HanssonERönnbäckL. Altered neuronal-glial signaling in glutamatergic transmission as a unifying mechanism in chronic pain and mental fatigue. Neurochem Res. (2004) 29(5):989–96. 10.1023/b:nere.0000021243.86287.43
38.
ZhaoJYeLLiuZCuiYDengDBaiSet alProtective effects of resveratrol on adolescent social isolation-induced anxiety-like behaviors via modulating nucleus accumbens spine plasticity and mitochondrial function in female rats. Nutrients. (2022) 14(21):4542. 10.3390/nu14214542
39.
JiangZRajamanickamSJusticeNJ. Local corticotropin-releasing factor signaling in the hypothalamic paraventricular nucleus. J Neurosci. (2018) 38:1874–90. 10.1523/JNEUROSCI.1492-17.2017
40.
SpitzerNC. How GABA generates depolarization. J Physiol. (2010) 588:757–8. 10.1113/jphysiol.2009.183574
41.
De LaurentiisAPiseraDLasagaMdel Carmen DíazMTheasSDuvilanskiBet alEffect of interleukin-6 and tumor necrosis factor-alpha on GABA release from mediobasal hypothalamus and posterior pituitary. Neuroimmunomodulation. (2000) 7:77–83. 10.1159/000026423
42.
LüscherBMöhlerH. Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience. F1000Res. (2019) 8:751. 10.12688/f1000research.18758.1
43.
FerriniFDe KoninckY. Microglia control neuronal network excitability via BDNF signalling. Neural Plast. (2013) 2013:429815. 10.1155/2013/429815
44.
TataDAAndersonBJ. The effects of chronic glucocorticoid exposure on dendritic length, synapse numbers and glial volume in animal models: implications for hippocampal volume reductions in depression. Physiol Behav. (2010) 99:186–93. 10.1016/j.physbeh.2009.09.008
45.
ListonCMillerMMGoldwaterDSRadleyJJRocherABHofPRet alStress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J Neurosci. (2006) 26:7870–4. 10.1523/JNEUROSCI.1184-06.2006
46.
CharneyDSManjiHK. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE. (2004) 2004(225):re5. 10.1126/stke.2252004re5.
47.
HardenLMKentSPittmanQJRothJ. Fever and sickness behavior: friend or foe?Brain Behav Immun. (2015) 50:322–33. 10.1016/j.bbi.2015.07.012
48.
RaisonCLMillerAH. The evolutionary significance of depression in pathogen host defense (PATHOS-D). Mol Psychiatry. (2012) 18:15–37. 10.1038/mp.2012.2
49.
CarpenterLLGawugaCETyrkaARLeeJKAndersonGMPriceLH. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology. (2010) 35:2617–23. 10.1038/npp.2010.159
50.
DickersonSSGableSLIrwinMRAzizNKemenyME. Social-evaluative threat and proinflammatory cytokine regulation: an experimental laboratory investigation. Psychol Sci. (2009) 20:1237–44. 10.1111/j.1467-9280.2009.02437.x
51.
BierhausAWolfJAndrassyMRohlederNHumpertPMPetrovDet alA mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A. (2003) 100:1920–5. 10.1073/pnas.0438019100
52.
PowellNDSloanEKBaileyMTArevaloJMMillerGEChenEet alSocial stress up-regulates inflammatory gene expression in the leukocyte transcriptome via β-adrenergic induction of myelopoiesis. Proc Natl Acad Sci U S A. (2013) 110:16574–9. 10.1073/pnas.1310655110
53.
RaberJ. Detrimental effects of chronic hypothalamic—pituitary—adrenal axis activation. Mol Neurobiol. (1998) 18:1–22. 10.1007/BF02741457
54.
OquendoMAEchavarriaGGalfalvyHGrunebaumMFBurkeABarreraAet alLower cortisol levels in depressed patients with comorbid post-traumatic stress disorder. Neuropsychopharmacology. (2002) 28:591–8. 10.1038/sj.npp.1300050
55.
BellouVBelbasisLTzoulakiIMiddletonLTIoannidisJPAEvangelouE. Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses. Alzheimers Dement. (2017) 13(4):406–18. 10.1016/j.jalz.2016.07.152
56.
GustafssonHNordströmANordströmP. Depression and subsequent risk of Parkinson disease: a nationwide cohort study. Neurology. (2015) 84(24):2422–9. 10.1212/WNL.0000000000001684
57.
PaceTWMletzkoTCAlagbeOMusselmanDLNemeroffCBMillerAHet alIncreased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. (2006) 163:1630–3. 10.1176/ajp.2006.163.9.1630
58.
BrownDWAndaRFTiemeierHFelittiVJEdwardsVJCroftJBet alAdverse childhood experiences and the risk of premature mortality. Am J Prev Med. (2009) 37:389–96. 10.1016/j.amepre.2009.06.021
59.
DowlatiYHerrmannNSwardfagerWLiuHShamLReimEKet alA meta-analysis of cytokines in major depression. Biol Psychiatry. (2010) 67:446–57. 10.1016/j.biopsych.2009.09.033
60.
MillerAHMaleticVRaisonCL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. (2009) 65:732–41. 10.1016/j.biopsych.2008.11.029
61.
DuchenMR. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Aspects Med. (2004) 25(4):365–451. 10.1016/j.mam.2004.03.001
62.
TirichenHYaigoubHXuWWuCLiRLiY. Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress. Front Physiol. (2021) 12:627837. 10.3389/fphys.2021.627837
63.
GuoCSunLChenXZhangD. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res. (2013) 8(21):2003–14. 10.3969/j.issn.1673-5374.2013.21.009
64.
VillapolS. Roles of peroxisome proliferator-activated receptor gamma on brain and peripheral inflammation. Cell Mol Neurobiol. (2018) 38(1):121–32. 10.1007/s10571-017-0554-5
65.
GlickDBarthSMacleodKF. Autophagy: cellular and molecular mechanisms. J Pathol. (2010) 221(1):3–12. 10.1002/path.2697.
66.
XuGShiY. Apoptosis signaling pathways and lymphocyte homeostasis. Cell Res. (2007) 17(9):759–71. 10.1038/cr.2007.52.
67.
LiangHWardWF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. (2006) 30(4):145–51. 10.1152/advan.00052.2006.
68.
ChengAWanRYangJLKamimuraNSonTGOuyangXet alInvolvement of PGC-1α in the formation and maintenance of neuronal dendritic spines. Nat Commun. (2012) 3:1250. 10.1038/ncomms2238.
69.
YanZ. Exercise, PGC-1alpha, and metabolic adaptation in skeletal muscle. Appl Physiol Nutr Metab. (2009) 34(3):424–7. 10.1139/H09-030.
70.
RethorstCDToupsMSGreerTLNakoneznyPACarmodyTJGrannemannBDet alPro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry. (2013) 18(10):1119–24. 10.1038/mp.2012.125.
71.
PedersenBK. The diseasome of physical inactivity–and the role of myokines in muscle–fat cross talk. J Physiol. (2009) 587(Pt 23):5559–68. 10.1113/jphysiol.2009.179515.
72.
HuMXTurnerDGeneraalEBosDIkramMKIkramMAet al Exercise interventions for the prevention of depression: a systematic review of meta-analyses. BMC Public Health. (2020) 20:1255. 10.1186/s12889-020-09323-y
73.
GordonBRMcDowellCPHallgrenMMeyerJDLyonsMHerringMP. Association of efficacy of resistance exercise training with depressive symptoms: meta-analysis and meta-regression analysis of randomized clinical trials. JAMA Psychiatry. (2018) 75:566–76. 10.1001/jamapsychiatry.2018.0572
74.
Klil-DroriSKlil-DroriAJPiraSRejS. Exercise intervention for late-life depression: a meta-analysis. J Clin Psychiatry. (2020) 81:19r12877. 10.4088/JCP.19r12877
75.
LarunLNordheimLVEkelandEHagenKBHeianF. Exercise in prevention and treatment of anxiety and depression among children and young people. Cochrane Database Syst Rev. (2006) 3:CD004691. 10.1002/14651858.CD004691.pub2
76.
KvamSKleppeCLNordhusIHHovlandA. Exercise as a treatment for depression: a metaanalysis. J Affect Disord. (2016) 202:67–86. 10.1016/j.jad.2016.03.063
77.
World Health Organization. WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization (2020).
78.
EvrenselAÜnsalverBÖCeylanME. Immune-kynurenine pathways and the gut microbiota-brain axis in anxiety disorders. Adv Exp Med Biol. (2020) 1191:155–67. 10.1007/978-981-32-9705-0_10
79.
SavitzJ. Role of kynurenine metabolism pathway activation in major depressive disorders. Curr Top Behav Neurosci. (2016) 31:249–67. 10.1007/7854_2016_12
80.
FujigakiHYamamotoYSaitoK. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: focus on cell type differences. Neuropharmacology. (2016) 112:264–74. 10.1016/j.neuropharm.2016.01.011
81.
SchwarczR. Kynurenines and glutamate: multiple links and therapeutic implications. Adv Pharmacol. (2016) 76:13–37. 10.1016/bs.apha.2016.01.005
82.
MartinKSAzzoliniMRuasJ. The kynurenine connection: how exercise shifts muscle tryptophan metabolism and affects energy homeostasis, the immune system, and the brain. Am J Physiol Physiol. (2020) 318:C818–30. 10.1152/ajpcell.00580.2019
83.
YauSYLiASoKF. Involvement of adult hippocampal neurogenesis in learning and forgetting. Neural Plast. (2015) 2015:717958. 10.1155/2015/717958.
84.
LiuWGeTLengYPanZFanJYangWet alThe role of neural plasticity in depression: from hippocampus to prefrontal cortex. Neural Plast. (2017) 2017:6871089. 10.1155/2017/6871089.
85.
PittengerCDumanRS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. (2008) 33(1):88–109. 10.1038/sj.npp.1301574.
86.
EliwaHBelzungCSurgetA. Adult hippocampal neurogenesis: is it the alpha and omega of antidepressant action?Biochem Pharmacol. (2017) 141:86–99. 10.1016/j.bcp.2017.08.005.
87.
PhillipsC. Brain-derived neurotrophic factor, depression, and physical activity: making the neuroplastic connection. Neural Plast. (2017) 2017:7260130. 10.1155/2017/7260130.
88.
ZhangJZhangW. Can irisin be a linker between physical activity and brain function?Biomol Concepts. (2016) 7(4):253–8. 10.1515/bmc-2016-0012.
89.
RudgeJSPasnikowskiEMHolstPLindsayRM. Changes in neurotrophic factor expression and receptor activation following exposure of hippocampal neuron/astrocyte cocultures to kainic acid. J Neurosci. (1995) 15(10):6856–67. 10.1523/JNEUROSCI.15-10-06856.1995.
90.
RanaTBehlTSehgalASrivastavaPBungauS. Unfolding the role of BDNF as a biomarker for treatment of depression. J Mol Neurosci. (2021) 71(10):2008–21. 10.1007/s12031-020-01754-x.
91.
Ben-ZeevTShoenfeldYHoffmanJR. The effect of exercise on neurogenesis in the brain. Isr Med Assoc J. (2022) 24(8):533–8.
92.
Almeida BarrosWMde Sousa FernandesMSSilvaRKPda SilvaKGda Silva SouzaAPRodrigues Marques SilvaMet alDoes the enriched environment alter memory capacity in malnourished rats by modulating BDNF expression?J Appl Biomed. (2021) 19(3):125–32. 10.32725/jab.2021.018.
93.
SilvermanMNDeusterPA. Biological mechanisms underlying the role of physical fitness in health and resilience. Interface Focus. (2014) 4(5):20140040. 10.1098/rsfs.2014.0040.
94.
RendeiroCRhodesJS. A new perspective of the hippocampus in the origin of exercise-brain interactions. Brain Struct Funct. (2018) 223(6):2527–45. 10.1007/s00429-018-1665-6.
95.
DavisAJMacCarronPCohenE. Social reward and support effects on exercise experiences and performance: evidence from parkrun. PLoS One. (2021) 16(9):e0256546. 10.1371/journal.pone.0256546.
96.
BeaulieuKHopkinsMGibbonsCOustricPCaudwellPBlundellJet alExercise training reduces reward for high-fat food in adults with overweight/obesity. Med Sci Sports Exerc. (2020) 52(4):900–8. 10.1249/MSS.0000000000002205.
97.
RiceSMPurcellRDe SilvaSMawrenDMcGorryPDParkerAG. The mental health of elite athletes: a narrative systematic review. Sports Med. (2016) 46(9):1333–53. 10.1007/s40279-016-0492-2.
98.
McGrathTBaskervilleRRogeroMCastellL. Emerging evidence for the widespread role of glutamatergic dysfunction in neuropsychiatric diseases. Nutrients. (2022) 14(5):917. 10.3390/nu14050917.
99.
FirthJStubbsBRosenbaumSVancampfortDMalchowBSchuchFet alAerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. Schizophr Bull. (2017) 43(3):546–56. 10.1093/schbul/sbw115.
100.
StubbsBVancampfortDHallgrenMFirthJVeroneseNSolmiMet alEPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European psychiatric association (EPA), supported by the international organization of physical therapists in mental health (IOPTMH). Eur Psychiatry. (2018) 54:124–44. 10.1016/j.eurpsy.2018.07.004.
101.
MeloMCDaher EdeFAlbuquerqueSGde BruinVM. Exercise in bipolar patients: A systematic review. J Affect Disord. (2016) 198:32–8. 10.1016/j.jad.2016.03.004
102.
TanBWPooleyJASpeelmanCP. A meta-analytic review of the efficacy of physical exercise interventions on cognition in individuals with autism spectrum disorder and ADHD. J Autism Dev Disord. (2016) 46(9):3126–43. 10.1007/s10803-016-2854-x.
103.
SunWYuMZhouX. Effects of physical exercise on attention deficit and other major symptoms in children with ADHD: a meta-analysis. Psychiatry Res. (2022) 311:114509. 10.1016/j.psychres.2022.114509.
104.
JylänkiPMbayTBymanAHakkarainenASääkslahtiAAunioP. Cognitive and academic outcomes of fundamental motor skill and physical activity interventions designed for children with special educational needs: a systematic review. Brain Sci. (2022) 12(8):1001. 10.3390/brainsci12081001.
105.
HegbergNJHayesJPHayesSM. Exercise intervention in PTSD: a narrative review and rationale for implementation. Front Psychiatry. (2019) 10:133. 10.3389/fpsyt.2019.00133.
106.
FreedmanDERichterMA. A narrative review of exercise and obsessive-compulsive disorder. Gen Hosp Psychiatry. (2021) 71:1–10. 10.1016/j.genhosppsych.2021.03.014
107.
AbrantesAMFarrisSGBrownRAGreenbergBDStrongDRMcLaughlinNCet alAcute effects of aerobic exercise on negative affect and obsessions and compulsions in individuals with obsessive-compulsive disorder. J Affect Disord. (2019) 245:991–7. 10.1016/j.jad.2018.11.074.
108.
López-OrtizSListaSValenzuelaPLPinto-FragaJCarmonaRCaraciFet alEffects of physical activity and exercise interventions on Alzheimer's disease: an umbrella review of existing meta-analyses. J Neurol. (2023) 270(2):711–25. 10.1007/s00415-022-11454-8.
109.
ZhangSZhenKSuQChenYLvYYuL. The effect of aerobic exercise on cognitive function in people with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. Int J Environ Res Public Health. (2022) 19(23):15700. 10.3390/ijerph192315700.
110.
FanBJabeenRBoBGuoCHanMZhangHet alWhat and how can physical activity prevention function on Parkinson's disease?Oxid Med Cell Longev. (2020) 2020:4293071. 10.1155/2020/4293071.
111.
ErnstMFolkertsAKGollanRLiekerECaro-ValenzuelaJAdamsAet alPhysical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. (2023) 1(1):CD013856. 10.1002/14651858.CD013856.pub2
112.
SteinackerJMLormesWReissneckerSLiuY. New aspects of the hormone and cytokine response to training. Eur J Appl Physiol. (2004) 91(4):382–91. 10.1007/s00421-003-0960-x.
113.
MagheriniFFiaschiTMarzocchiniRMannelliMGamberiTModestiPAet alOxidative stress in exercise training: the involvement of inflammation and peripheral signals. Free Radic Res. (2019) 53(11–12):1155–65. 10.1080/10715762.2019.1697438.
114.
CastellL. Glutamine supplementation in vitro and in vivo, in exercise and in immunodepression. Sports Med. (2003) 33(5):323–45. 10.2165/00007256-200333050-00001.
115.
SaundersMN. The physiology of boredom, depression and senile dementia. Med Hypotheses. (1996) 46(5):463–6. 10.1016/s0306-9877(96)90026-2.
116.
KirbyEDMuroySESunWGCovarrubiasDLeongMJBarchasLAet alAcute stress enhances adult rat hippocampal neurogenesis and activation of newborn neurons via secreted astrocytic FGF2. Elife. (2013) 2:e00362. 10.7554/eLife.00362.
117.
FarooqiAGilliesCSathanapallyHAbnerSSeiduSDaviesMJet alA systematic review and meta-analysis to compare the prevalence of depression between people with and without type 1 and type 2 diabetes. Prim Care Diabetes. (2022) 16(1):1–10. 10.1016/j.pcd.2021.11.001.
118.
ParkSYLeeKUmYJPaekSRyouIS. Association between physical activity and depressive mood among Korean adults with chronic diseases. Korean J Fam Med. (2018) 39(3):185–90. 10.4082/kjfm.2018.39.3.185.
119.
HanyuH. Diabetes-related dementia. Adv Exp Med Biol. (2019) 1128:147–60. 10.1007/978-981-13-3540-2_8.
120.
HassanASharma KandelRMishraRGautamJAlarefAJahanN. Diabetes mellitus and Parkinson's disease: shared pathophysiological links and possible therapeutic implications. Cureus. (2020) 12(8):e9853. 10.7759/cureus.9853.
121.
EstricCCalatiRLopez-CastromanJ. Adverse childhood experiences and neurocognition in borderline personality disorder: a call-to-action perspective review. Harv Rev Psychiatry. (2022) 30(4):248–60. 10.1097/HRP.0000000000000344
Summary
Keywords
exercise, neuroimmunology, depression, glutamate, inflammation, stress
Citation
Baskerville R, McGrath T and Castell L (2023) The effects of physical activity on glutamate neurotransmission in neuropsychiatric disorders. Front. Sports Act. Living 5:1147384. doi: 10.3389/fspor.2023.1147384
Received
18 January 2023
Accepted
17 February 2023
Published
06 March 2023
Volume
5 - 2023
Edited by
Muaz Belviranli, Selçuk University, Türkiye
Reviewed by
Luodan Yang, South China Normal University, China Rolf Sprengel, Max Planck Institute for Medical Research (MPIMF), Germany
Updates
Copyright
© 2023 Baskerville, mcgrath and Castell.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Richard Baskerville rbaskerville@brookes.ac.uk
Specialty Section: This article was submitted to Exercise Physiology, a section of the journal Frontiers in Sports and Active Living
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.